Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...

Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic improvement at Week 12 of its phase 2 ulcerative colitis trial. The new duvakitug data also clear up the ...

Merck has taken steps in mergers and acquisition to diversify its pipeline and product offerings, including the $10.8 billion acquisition of Prometheus Biosciences and a major licensing deal with ...

Merck's expansion into cardiovascular treatments and advancements in immunology and inflammation, partly through the Prometheus transaction, are seen as potential growth drivers by analysts.

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

Merck issued a US$6bn jumbo bond on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune diseases as it ...

Merck embraces precision medicine and leverages data from Prometheus and applies its oncology expertise to inflammatory bowel disease. Their pipeline aims to transform treatments for chronic ...